A large meta-analysis of literature data showed that the HER2-enriched biomarker identifies breast cancer patients with a higher chance of achieving a complete pathological response following neoadjuvant anti-HER2-based therapy beyond hormonal receptor status and chemotherapy [101]. This evidence concerns the gene ERBB2 and breast carcinoma.